More Data for Ustekinumab in Crohn’s Disease

Briefly noted: C Ma et al. Inflamm Bowel Dis 2017; 23: 833-9.  This retrospective study examined the response to ustekinumab in 104 patients with Crohn’s disease.  All patients had achieved a steroid-free ustekinumab induction.  92.3% had failed anti-TNFα therapy.

Key findings:

  • 71.8% maintained a response at 52 weeks
  • 64.4% maintained an endoscopic or radiographic response

4 thoughts on “More Data for Ustekinumab in Crohn’s Disease

    • One reason for the impressive results was that all had undergone an ustekinumab induction and therefore had already responded. This study shows mainly that if one responds to ustekinumab, they are likely to maintain a response.

  1. Pingback: Ustekinumab for Ulcerative Colitis (UNIFI Trial) | gutsandgrowth

  2. Pingback: Dose Escalation of Ustekinumab & Support Tool “Should I Have IBD Surgery?” | gutsandgrowth

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.